AML
MCID: LKM061
MIFTS: 83

Leukemia, Acute Myeloid (AML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid 57 38
Acute Myeloid Leukemia 38 12 76 53 75 37 29 6 43 15
Leukemia, Acute Myelogenous 57 75 13 40
Acute Myelogenous Leukemia 12 76 53 15
Leukemia, Acute Myeloid, Susceptibility to 57 29 6
Acute Undifferentiated Leukemia 59 55 73
Acute Myeloblastic Leukemia 12 76 75
Acute Biphenotypic Leukemia 59 73
Leukemia, Myelocytic, Acute 12 73
Acute Myelocytic Leukemia 76 75
Leukemia, Myeloid, Acute 44 40
Aml 57 75
Acute Myeloid Leukaemia with Myelodysplasia-Related Features 59
Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 59
Leukemia, Acute Myeloid, Reduced Survival in, Somatic 57
Acute Myeloid Leukemia with Cebpa Somatic Mutations 59
Acute Myeloid Leukemia with Multilineage Dysplasia 59
Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic 57
Aml with Myelodysplasia-Related Features 59
Pure Familial Acute Myeloid Leukemia 59
Leukemia, Acute Myeloid, Somatic 57
Aml with Cebpa Somatic Mutations 59
Inherited Acute Myeloid Leukemia 59
Acute Non-Lymphoblastic Leukemia 75
Acute Myeloid Leukemia, Somatic 57
Aml with Multilineage Dysplasia 59
Acute Non-Lymphocytic Leukemia 75
Aml - Acute Myeloid Leukemia 12
Bilineal Acute Leukemia 59
Pure Familial Aml 59
Inherited Aml 59
Familial Aml 59

Characteristics:

Orphanet epidemiological data:

59

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations
many genes with somatic mutation


HPO:

32
leukemia, acute myeloid:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 601626
Disease Ontology 12 DOID:9119
ICD9CM 35 205.0
MeSH 44 D015470
NCIt 50 C27753 C3171
SNOMED-CT 68 17788007 91861009
ICD10 via Orphanet 34 C92.0 C92.8 C95.0
UMLS via Orphanet 74 C1292773 C0023464 C0280141 more
MESH via Orphanet 45 D015456
KEGG 37 H00003
SNOMED-CT via HPO 69 263681008 413443009 240305000

Summaries for Leukemia, Acute Myeloid

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to core binding factor acute myeloid leukemia and leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Folotyn and Ixempra have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : 12 A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : 53 Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : 75 Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : 76 Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 625)
# Related Disease Score Top Affiliating Genes
1 core binding factor acute myeloid leukemia 33.7 CEBPA FLT3 JAK2 KIT KRAS NRAS
2 leukemia 33.5 CEBPA CSF3R ETV6 FLT3 JAK2 KIT
3 acute myeloblastic leukemia with maturation 33.5 FLT3 KIT NPM1
4 cytogenetically normal acute myeloid leukemia 33.5 CEBPA FLT3 NPM1
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.2 ETV6 FLT3 KIT RUNX1
6 acute erythroid leukemia 33.1 CEBPA GATA2 JAK2 PICALM
7 acute leukemia 32.9 CEBPA ETV6 FLT3 JAK2 KIT MLLT10
8 acute myeloblastic leukemia without maturation 32.8 FLT3 NPM1
9 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.7 CEBPA FLT3 KIT RUNX1
10 myeloid leukemia 32.4 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
11 myeloid sarcoma 31.2 FLT3 KIT NPM1
12 lymphoid leukemia 31.2 ETV6 FLT3 JAK2
13 leukemia, chronic myeloid 30.9 CSF3R ETV6 FLT3 GATA2 JAK2 KIT
14 myelodysplastic syndrome 30.8 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
15 myeloproliferative neoplasm 30.8 JAK2 KIT PTPN11
16 precursor t-cell acute lymphoblastic leukemia 30.8 ETV6 FLT3 MLLT10 NUP214 PICALM
17 chronic myelomonocytic leukemia 30.7 CSF3R DNMT3A ETV6 FLT3 JAK2 KIT
18 aleukemic leukemia cutis 30.6 FLT3 NPM1 RUNX1
19 myeloma, multiple 30.6 JAK2 KIT KRAS NRAS PTPN11
20 leukemia, chronic lymphocytic 2 30.6 KRAS NRAS PTPN11
21 severe congenital neutropenia 30.6 CSF3R JAK2 PTPN11
22 acute promyelocytic leukemia 30.5 CEBPA CSF3R FLT3 NPM1 NRAS RUNX1
23 myelodysplastic myeloproliferative cancer 30.5 CSF3R JAK2 NRAS PTPN11
24 juvenile myelomonocytic leukemia 30.5 DNMT3A FLT3 JAK2 KRAS NRAS PTPN11
25 leukemia, acute lymphoblastic 30.5 ETV6 FLT3 PICALM RUNX1
26 atypical chronic myeloid leukemia 30.4 CSF3R JAK2 RUNX1
27 8p11 myeloproliferative syndrome 30.4 FLT3 KIT RUNX1
28 aplastic anemia 30.4 CSF3R FLT3 GATA2 NRAS TERT
29 acute t cell leukemia 30.4 LPP MLLT10 NUP214
30 childhood leukemia 30.4 ETV6 PTPN11 RUNX1
31 subacute myeloid leukemia 30.3 FLT3 JAK2
32 familial acute myeloid leukemia with mutated cebpa 12.6
33 acute biphenotypic leukemia 12.5
34 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.4
35 cebpa-associated familial acute myeloid leukemia 12.3
36 aml with myelodysplasia-related features 12.1
37 megakaryocytic leukemia 11.9
38 lymphedema, primary, with myelodysplasia 11.7
39 platelet disorder, familial, with associated myeloid malignancy 11.6
40 acute monoblastic leukemia 11.6
41 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 11.5
42 acute myeloid leukemia with minimal differentiation 11.5
43 myelodysplastic syndrome with excess blasts 11.5
44 acute non lymphoblastic leukemia 11.3
45 shwachman-diamond syndrome 2 11.3
46 erythroleukemia, familial 11.3
47 acute myeloid leukemia with t(8;16)(p11;p13) translocation 11.3
48 acute myeloid leukemia with t(9;11)(p22;q23) 11.3
49 acute myeloid leukemia with t(6;9)(p23;q34) 11.3
50 acute myeloid leukemia with npm1 somatic mutations 11.3

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:



Diseases related to Leukemia, Acute Myeloid

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

57
Hematology:
acute myelogenous leukemia (aml)


Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

32
# Description HPO Frequency HPO Source Accession
1 acute myeloid leukemia 32 HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 CEBPA CSF3R DNMT3A ETV6 KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 CEBPA CSF3R DNMT3A ETV6 FLT3 GATA2
2 hematopoietic system MP:0005397 10.43 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
3 endocrine/exocrine gland MP:0005379 10.39 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
4 homeostasis/metabolism MP:0005376 10.39 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
5 mortality/aging MP:0010768 10.39 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
6 growth/size/body region MP:0005378 10.38 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
7 immune system MP:0005387 10.37 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
8 embryo MP:0005380 10.34 DNMT3A ETV6 GATA2 JAK2 KIT KRAS
9 cardiovascular system MP:0005385 10.32 CEBPA CHIC2 CSF3R ETV6 GATA2 KIT
10 integument MP:0010771 10.22 CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11 liver/biliary system MP:0005370 10.16 CEBPA GATA2 JAK2 KIT KRAS NPM1
12 neoplasm MP:0002006 10.14 CEBPA ETV6 FLT3 JAK2 KIT KRAS
13 digestive/alimentary MP:0005381 10.11 CEBPA ETV6 KIT KRAS NRAS PTPN11
14 normal MP:0002873 10.02 CEBPA ETV6 GATA2 JAK2 KIT KRAS
15 no phenotypic analysis MP:0003012 9.97 CEBPA ETV6 FLT3 KIT KRAS NRAS
16 reproductive system MP:0005389 9.9 CEBPA CHIC2 CSF3R DNMT3A GATA2 JAK2
17 pigmentation MP:0001186 9.73 CHIC2 KIT KRAS NRAS PICALM PTPN11
18 skeleton MP:0005390 9.61 FLT3 JAK2 KIT KRAS NRAS PTPN11
19 vision/eye MP:0005391 9.23 CEBPA CHIC2 KIT KRAS NPM1 NRAS

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
2
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
3
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
4
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
5
Arcapta 18 INDACATEROL MALEATE Novartis July 2011

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
3
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
5
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
6
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
7
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
8
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
9
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
12
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
13 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123948-87-8, 119413-54-6 60700
15
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
16
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
18
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
19
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
20
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
23
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 171228-49-2 147912
24
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
25
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
29
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
30 Molgramostim Investigational Phase 4,Phase 3 99283-10-0
31
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Interferon-alpha Phase 4,Phase 2,Phase 1,Not Applicable
46 interferons Phase 4,Phase 2,Phase 1,Not Applicable
47 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
50 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2605)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
7 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
8 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
9 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
10 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
11 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
12 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
13 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
14 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
15 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
16 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
17 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
18 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
20 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
21 LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Terminated NCT01198054 Phase 4 Lenalidomide
22 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
23 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
24 Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML Not yet recruiting NCT03727750 Phase 4 Gemtuzumab Ozogamicin
25 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
26 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
27 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
28 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
29 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
30 A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
31 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
32 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
33 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
34 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
35 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
36 the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate
37 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
38 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia Unknown status NCT00342316 Phase 3
39 Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia Unknown status NCT02244658 Phase 3 rhTPO
40 Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia Unknown status NCT02171117 Phase 3
41 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3 Decitabine
42 Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) Unknown status NCT01145846 Phase 3 Cytarabine plus Daunorubicin [Arm II (AD regimen)]
43 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
44 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Unknown status NCT02474290 Phase 2, Phase 3 Sorafenib
45 Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia Unknown status NCT00224614 Phase 3
46 Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status NCT00715637 Phase 3 Daunorubicin and Cytarabine;Amonafide and Cytarabine
47 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
48 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
49 Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
50 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia 29 CBFB CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2 JAK2 KIT KRAS LPP MLF1 MLLT10 NPM1 NSD1 NSD3 NUP214 PICALM RUNX1 SH3GL1 TERT
2 Leukemia, Acute Myeloid, Susceptibility to 29

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

41
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells Affected by disease
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 5993)
# Title Authors Year
1
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
2
TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. ( 30551433 )
2019
3
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia. ( 30318867 )
2019
4
ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. ( 30322352 )
2019
5
Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. ( 30270523 )
2019
6
FLT3 inhibitors in acute myeloid leukemia: Current and future. ( 30270754 )
2019
7
Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. ( 30105796 )
2019
8
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )
2018
9
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
10
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
11
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )
2018
12
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
13
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
14
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
15
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )
2018
16
Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )
2018
17
MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )
2018
18
Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )
2018
19
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )
2018
20
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
21
Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )
2018
22
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
23
Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )
2018
24
Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )
2018
25
Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )
2018
26
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )
2018
27
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )
2018
28
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )
2018
29
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
30
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
31
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )
2018
32
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
33
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )
2018
34
Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )
2018
35
Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )
2018
36
Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )
2018
37
Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )
2018
38
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )
2018
39
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
40
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )
2018
41
<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )
2018
42
Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )
2018
43
Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes. ( 29330024 )
2018
44
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. ( 29976748 )
2018
45
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( 29119643 )
2018
46
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
47
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )
2018
48
Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )
2018
49
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )
2018
50
Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )
2018

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

75
# Symbol AA change Variation ID SNP ID
1 CEBPA p.His84Leu VAR_072677 rs28931590
2 JAK2 p.Lys607Asn VAR_032696 rs121912472
3 JAK2 p.Val617Phe VAR_032697 rs77375493
4 SETBP1 p.Gly870Ser VAR_063809 rs267607040
5 SETBP1 p.Ser854Ala VAR_069848
6 SETBP1 p.Gly870Arg VAR_069854
7 SETBP1 p.Ile871Ser VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

6 (show top 50) (show all 750)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh37 Chromosome 12, 11992136: 11992136
2 ETV6 NM_001987.4(ETV6): c.226G> T (p.Glu76Ter) single nucleotide variant Pathogenic rs121434637 GRCh38 Chromosome 12, 11839202: 11839202
3 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh37 Chromosome 12, 12043928: 12043929
4 ETV6 NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly) insertion Pathogenic rs587776710 GRCh38 Chromosome 12, 11890994: 11890995
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
11 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
12 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
13 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
14 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 GRCh38 Chromosome 12, 25245347: 25245347
15 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
16 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
17 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
18 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
19 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh38 Chromosome 12, 25245356: 25245358
20 KRAS NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly) duplication Pathogenic rs606231202 GRCh37 Chromosome 12, 25398290: 25398292
21 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
23 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
24 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
25 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
26 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
27 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
28 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
29 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
30 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
31 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
32 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
33 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
34 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh38 Chromosome 4, 54733155: 54733155
35 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
36 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
37 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
38 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
39 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
40 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
41 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
42 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
43 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
44 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
45 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh38 Chromosome 5, 171410540: 171410543
46 NPM1 NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs) duplication Pathogenic rs587776806 GRCh37 Chromosome 5, 170837544: 170837547
47 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
48 NPM1 NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh37 Chromosome 5, 170837547: 170837548
49 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh38 Chromosome 5, 171410543: 171410544
50 NPM1 NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs) insertion Pathogenic rs587776806 GRCh37 Chromosome 5, 170837547: 170837548

Copy number variations for Leukemia, Acute Myeloid from CNVD:

7 (show top 50) (show all 491)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13336 1 1 124300000 Insertion Acute myeloid leukemia
2 13759 1 1 28000000 Deletion Acute myeloid leukemia
3 14790 1 110122000 110569000 Gain or loss Acute myeloid leukemia
4 17466 1 142902432 245422360 Duplication Acute myeloid leukemia
5 18096 1 143961000 247125000 Gain or loss Acute myeloid leukemia
6 20826 1 154656757 154656845 Amplification Acute myeloid leukemia
7 24589 1 182359000 182787000 Loss Acute myeloid leukemia
8 26098 1 197094625 197094734 Amplification Acute myeloid leukemia
9 26100 1 197094796 197094905 Amplification Acute myeloid leukemia
10 27148 1 204981000 205049000 Gain or loss Acute myeloid leukemia
11 27263 1 206041820 206041907 Amplification Acute myeloid leukemia
12 27859 1 214500000 224100000 Deletion Acute myeloid leukemia
13 28491 1 222606000 222909000 Gain or loss Acute myeloid leukemia
14 29341 1 230606000 230646000 Gain or loss Acute myeloid leukemia
15 32943 1 40683565 40683656 Amplification Acute myeloid leukemia
16 32944 1 40686494 40686582 Amplification Acute myeloid leukemia
17 33084 1 42072000 42456000 Gain or loss Acute myeloid leukemia
18 35033 1 5913000 7696000 Gain or loss Acute myeloid leukemia
19 35608 1 65296705 65296779 Amplification Acute myeloid leukemia
20 35769 1 67074000 69951000 Gain or loss Acute myeloid leukemia
21 36085 1 71305902 71305987 Amplification miR-186 Acute myeloid leukemia
22 38187 10 1 6700000 Insertion IL15RA Acute myeloid leukemia
23 38188 10 1 6700000 Insertion PRKCQ Acute myeloid leukemia
24 38677 10 104186259 104186331 Deletion Acute myeloid leukemia
25 38804 10 105144000 105144148 Deletion Acute myeloid leukemia
26 39144 10 110889374 110889450 Deletion Acute myeloid leukemia
27 39902 10 122017230 122017301 Deletion let-7a-2 Acute myeloid leukemia
28 41668 10 21893278 22027081 Loss MLLT10 Acute myeloid leukemia
29 41990 10 27075530 27189965 Translate SSH3BP1 Acute myeloid leukemia
30 43278 10 46100000 49900000 Copy number GDF10 Acute myeloid leukemia
31 44445 10 57165247 57165335 Deletion Acute myeloid leukemia
32 44874 11 64658609 64658718 Deletion miR-192 Acute myeloid leukemia
33 45369 10 70521000 135283000 Gain Acute myeloid leukemia
34 47681 10 96486000 100815000 Loss Acute myeloid leukemia
35 49592 11 108316750 133951370 Triplication Acute myeloid leukemia
36 50142 11 114500000 121200000 Copy number MLL Acute myeloid leukemia
37 50190 11 115400000 120700000 Insertion DDX6 Acute myeloid leukemia
38 50191 11 115400000 120700000 Insertion ETS1 Acute myeloid leukemia
39 50192 11 115400000 120700000 Insertion FLI1 Acute myeloid leukemia
40 50193 11 115400000 120700000 Insertion MLL Acute myeloid leukemia
41 50261 11 116297361 116448564 Loss Acute myeloid leukemia
42 50346 11 117203762 118563610 Amplification Acute myeloid leukemia
43 50385 11 117603158 117860329 Duplication Acute myeloid leukemia
44 50437 11 117820656 117856311 Gain MLL Acute myeloid leukemia
45 50640 11 118585028 127052111 Deletion Acute myeloid leukemia
46 51468 11 126537000 130235000 Gain Acute myeloid leukemia
47 51512 11 127394408 133951311 Amplification Acute myeloid leukemia
48 52810 11 2016406 2019065 Methylation H19 Acute myeloid leukemia
49 53744 11 32409321 32457081 Mutation WT1 Acute myeloid leukemia
50 54217 11 39671000 39746000 Loss Acute myeloid leukemia

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

37
# Name Kegg Source Accession
1 Acute myeloid leukemia hsa05221
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 CEBPA CSF3R FLT3 JAK2 KIT KRAS
2
Show member pathways
13.17 CSF3R FLT3 JAK2 KIT KRAS NRAS
3
Show member pathways
12.75 CSF3R FLT3 JAK2 KIT KRAS NRAS
4
Show member pathways
12.56 FLT3 KIT KRAS NRAS PTPN11
5
Show member pathways
12.44 CEBPA FLT3 KIT KRAS NRAS PTPN11
6 12.39 CEBPA GATA2 JAK2 KIT RUNX1
7
Show member pathways
12.38 JAK2 KRAS NRAS PTPN11
8
Show member pathways
12.32 FLT3 KRAS NRAS PTPN11
9
Show member pathways
12.27 KIT KRAS NRAS PTPN11
10
Show member pathways
12.2 FLT3 JAK2 KRAS NRAS
11
Show member pathways
12.2 CSF3R JAK2 KRAS NRAS PTPN11
12
Show member pathways
12.12 JAK2 KRAS NRAS PTPN11
13 12.08 CEBPA ETV6 FLT3 RUNX1
14 12 CEBPA CSF3R FLT3 JAK2 KIT KRAS
15 11.97 FLT3 JAK2 KIT NPM1
16
Show member pathways
11.84 JAK2 KRAS NRAS
17 11.8 JAK2 KRAS NRAS
18 11.78 CSF3R FLT3 KIT
19 11.64 CEBPA KIT NRAS
20 11.54 GATA2 NPM1 TERT
21
Show member pathways
11.54 FLT3 KIT KRAS NRAS
22
Show member pathways
11.53 JAK2 KRAS NRAS
23 11.37 FLT3 KIT KRAS NRAS
24 11.3 CSF3R JAK2 KRAS NRAS PTPN11
25 11.19 JAK2 KRAS NRAS
26 10.92 DNMT3A ETV6 FLT3
27 10.71 KRAS NRAS

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2 nucleus GO:0005634 9.8 CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3 focal adhesion GO:0005925 9.02 JAK2 KRAS LPP NPM1 NUP214
4 cytosol GO:0005829 10.03 ETV6 FLT3 JAK2 KRAS LPP MLLT10

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 FLT3 JAK2 KIT KRAS NPM1
2 negative regulation of gene expression GO:0010629 9.78 GATA2 PICALM RUNX1 TERT
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 FLT3 JAK2 KIT
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 FLT3 JAK2 KIT
5 MAPK cascade GO:0000165 9.55 FLT3 JAK2 KIT KRAS NRAS
6 interleukin-6-mediated signaling pathway GO:0070102 9.54 JAK2 PTPN11
7 positive regulation of MAP kinase activity GO:0043406 9.54 FLT3 KIT KRAS
8 megakaryocyte development GO:0035855 9.52 KIT PTPN11
9 hematopoietic stem cell proliferation GO:0071425 9.49 ETV6 RUNX1
10 regulation of myeloid cell differentiation GO:0045637 9.46 CSF3R RUNX1
11 homeostasis of number of cells within a tissue GO:0048873 9.43 GATA2 KRAS PTPN11
12 hemopoiesis GO:0030097 9.35 FLT3 GATA2 KIT PICALM RUNX1
13 myeloid progenitor cell differentiation GO:0002318 9.32 FLT3 KIT
14 cytokine-mediated signaling pathway GO:0019221 9.17 CEBPA CSF3R FLT3 JAK2 KIT KRAS

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 CEBPA CHIC2 CSF3R DNMT3A ETV6 FLT3
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.55 CEBPA DNMT3A ETV6 GATA2 RUNX1
3 nucleotide binding GO:0000166 9.35 FLT3 JAK2 KIT KRAS NRAS
4 insulin receptor substrate binding GO:0043560 9.32 JAK2 PTPN11
5 peptide hormone receptor binding GO:0051428 9.26 JAK2 PTPN11

Sources for Leukemia, Acute Myeloid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....